Automated And Closed Cell Therapy Processing Systems Market Report 2026

Automated And Closed Cell Therapy Processing Systems Market Overview

• Automated And Closed Cell Therapy Processing Systems market size has reached to $1.53 billion in 2025 • Expected to grow to $3.34 billion in 2030 at a compound annual growth rate (CAGR) of 16.7% • Growth Driver: Growing Demand For Personalized Medicine Fueling The Growth Of The Market Due To Regulatory Support And Therapeutic Innovation • Market Trend: Technological Innovations Driving Efficiency And Quality In Cell Therapy Manufacturing Through Advanced Automation And Intelligent Control Systems • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Automated And Closed Cell Therapy Processing Systems Market?

Automated and closed cell therapy processing systems refer to integrated platforms that perform multiple steps of cell therapy manufacturing within a sealed and controlled environment. These systems reduce the need for manual handling, minimizing contamination risks and ensuring consistent, high-quality cell products. By automating processes such as cell isolation, expansion, and formulation, they improve efficiency, reproducibility, and compliance with strict regulatory requirements. The main components of automated and closed-cell therapy processing systems include software, hardware, and consumables. Software in automated and closed-cell therapy processing systems is specialized programming that controls, monitors, and manages the precise and sterile manufacturing of cell-based therapies. It uses multiple technologies such as microfluidics, robotics, bioreactors, single-use technology, and three-dimensional (3D) cell culture, and different workflows include cryopreservation, separation, fill-finish, expansion, apheresis, and others. It is applied for oncology, regenerative medicine, autoimmune diseases, infectious diseases, and cardiovascular diseases by various end-users such as pharmaceutical companies, biotechnology companies, research institutes, contract manufacturing organizations, and hospitals.

What Is The Automated And Closed Cell Therapy Processing Systems Market Growth Forecast?

The automated and closed cell therapy processing systems market size is expected to see rapid growth in the next few years. It will grow to $3.34 billion in 2030 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to development of integrated closed-system platforms, advancements in robotics and microfluidics, growth of cell and gene therapy pipelines, rising regulatory compliance standards, increasing contract manufacturing organizations (cramos) for cell therapies. Major trends in the forecast period include increasing adoption of single-use and closed systems, rising demand for automated cell therapy workflows, focus on minimizing contamination and enhancing safety, integration of multi-step cell processing platforms, expansion of regenerative medicine and oncology applications.

Global Automated And Closed Cell Therapy Processing Systems Market Segmentation

1) By Component: Software, Hardware, Consumables 2) By Technology: Microfluidics, Robotics, Bioreactors, Single-Use Technology, Three-Dimensional (3D) Cell Culture 3) By Workflow: Cryopreservation, Separation, Fill-Finish, Expansion, Apheresis, Other Workflows 4) By Application: Oncology, Regenerative Medicine, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases 5) By End User: Pharmaceutical Companies, Biotechnology Companies, Research Institutes, Contract Manufacturing Organizations, Hospitals Subsegments: 1) By Software: Process Control Software, Data Management Software, Quality Monitoring Software, Workflow Automation Software, Integration Software 2) By Hardware: Cell Separation Devices, Bioreactors, Fluid Handling Systems, Centrifuges, Tubing And Connectors 3) By Consumables: Sterile Bags, Culture Media, Reagents And Buffers, Filters And Cartridges, Single-Use Tubing Sets

What Is The Driver Of The Automated And Closed Cell Therapy Processing Systems Market?

The growing demand for personalized medicine is expected to propel the growth of the automated and closed-cell therapy processing systems market going forward. Personalized medicine refers to medical treatments that are tailored to an individual’s genetic, molecular, or cellular profile to maximize efficacy and minimize adverse effects. The growing demand for personalized medicine is driven by strengthened regulatory frameworks and incentives that prioritize approval of targeted and curative therapies over broad-use drugs. Automated and closed-cell therapy processing systems support personalized medicine by enabling manufacturers to produce consistent, high-quality, patient-specific cell therapies that meet strict regulatory standards. For instance, in May 2025, according to the Personalized Medicine Coalition (PMC), a US-based non-profit organization, the FDA approved 18 new personalized medicines in 2024, including six gene- or cell-based therapies, representing roughly 38 percent of all new molecular entities. Therefore, the growing demand for personalized medicine is driving the growth of the automated and closed-cell therapy processing systems market.

Key Players In The Global Automated And Closed Cell Therapy Processing Systems Market

Major companies operating in the automated and closed cell therapy processing systems market are Thermo Fisher Scientific Inc., Fresenius SE & Co. KGaA, Danaher Corporation, Merck KGaA, Parker Hannifin Corp., Corning Incorporated, Kawasaki Heavy Industries Ltd., Dover Corporation, Lonza Group AG, Terumo Corporation, Sartorius AG, Charles River Laboratories International Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Hamilton Company, Repligen Corporation, Cellares Inc., Ori Biotech Ltd., Autolus Therapeutics Plc.

Global Automated And Closed Cell Therapy Processing Systems Market Trends and Insights

Major companies operating in the automated and closed cell therapy processing systems market are focusing on developing advanced solutions, such as cell preparation platforms, to reduce manual labor and the risk of contamination during cell processing. Cell preparation platforms are automated systems used to isolate, process, and prepare cells efficiently for further analysis or clinical use. For instance, in October 2024, Sino-Biocan Biotechnology Ltd., a China-based biotech company, launched the WUKONG Automated, Closed, Integrated Cell Processing System, which marks a major advancement in cell therapy manufacturing, providing a fully automated, closed platform that streamlines processes from blood collection to cell culture and final filling. It is designed to serve hospitals, pharmaceutical research and development teams, and contract development and manufacturing organizations by improving efficiency, reducing contamination risks, and ensuring good manufacturing practice-grade consistency through intelligent controls and real-time monitoring.

What Are Latest Mergers And Acquisitions In The Automated And Closed Cell Therapy Processing Systems Market?

In March 2024, Donaldson Company Inc., a US-based filtration company, acquired Univercells Technologies for $157.28 million (€136 million). Through this acquisition, Donaldson aims to expand its life sciences portfolio by integrating Univercells Technologies' automated and closed biomanufacturing platforms to offer end-to-end solutions for cell and gene therapy production. Univercells Technologies is a Belgium-based provider of automated and closed cell therapy processing systems.

Regional Outlook

North America was the largest region in the automated and closed cell therapy processing systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Automated And Closed Cell Therapy Processing Systems Market?

The automated and closed cell therapy processing systems market includes revenues earned by entities by providing services such as cell separation and isolation, quality control integration, genetic modification, and cell activation. The market value includes the value of related goods sold by the service provider or included within the service offering. The automated and closed cell therapy processing systems market also includes sales of control systems, single-use consumables, automated cell washing systems, and closed-system fluid handling components. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.